Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 17/20 | 0.50 |
| ▸ | BCL2 | P10415 | 14/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 14/20 | 0.50 |
| ▸ | BCL2A1 | Q16548 | 11/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.48 |
| ▸ | PNLIP | P16233 | 1/20 | 0.42 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472646 | 0.90 | BCL2L1 (0.57) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL3474740 | 0.81 | BCL2L1 (0.67) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL19420192 | 0.78 | BCL2L1 (0.64) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL19425476 | 0.74 | BCL2L1 (0.71) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL12238812 | 0.71 | BCL2L1 (0.78) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL21116450 | 0.69 | BCL2L1 (0.83) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL3473620 | 0.68 | PGR (0.48) | GAA | |
| SCHEMBL3475235 | 0.67 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL3473744 | 0.67 | BCL2L1 (0.60) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL352771 | 0.66 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2L1 464/4885BCL2 132/4885MCL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.